NEW YORK, Oct. 24 /PRNewswire/ -- NexGenix Pharmaceuticals, a privately held biotechnology company focused on developing drugs to treat the orphan- designated tumor suppressor disorder neurofibromatosis and related sporadic tumors, today announced that Allan E. Rubenstein, MD, Chief Executive Officer of NexGenix will be presenting at the Rodman & Renshaw 8th Annual Healthcare Conference on Wednesday, November 8th, 2006 at 10:35 am EST at the New York Palace Hotel, NY.
Dr. Rubenstein will be providing an overview of NexGenix and discussing recent company highlights. The presentation will be webcast live and can be accessed for a further 90 days by visiting www.wsw.com/webcast/rrshq10/nexgenix/.
The Rodman & Renshaw 8th Annual Healthcare Conference, attended by investors, venture capitalists, company executives, scientists and other industry leaders, will include presentations by over 300 companies, as well as experts from the medical, scientific and investment communities.
About NexGenix Pharmaceuticals
NexGenix Pharmaceuticals is a US-based biotechnology company focused on drug development for Neurofibromatosis Types 1 and 2 and related sporadic tumors. Neurofibromatosis, or NF, is a genetic disorder characterized by the development of tumors along nerves. These slow growing tumors are resistant to radiation and chemotherapy and the only current treatment is repeated surgical removal. NexGenix has assembled a team of top NF clinicians and researchers on its Scientific Advisory Board and has developed a proprietary screening platform for both Neurofibromatosis Type 1 and 2. NexGenix will soon seek an IND for a unique treatment for NF1. A targeted treatment for NF2 is in preclinical development.
For more information, please visit the NexGenix website at www.nexgenixpharm.com
This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Certain information contained in this news release is forward-looking and is subject to unknown risks and uncertainties. The actual results, performance or achievements of the company may differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements.
NexGenix Pharmaceuticals
CONTACT: For further information, or to arrange for interviews pleasecontact Michelle Morin, BS, Director of Corporate Development, NexgenixPharmaceuticals, +1-212-974-3006, mmorin@nexgenixpharm.com
